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1,10-Phenanthroline (phen, 5), 1,10-phenanthroline-5,6-dione (phendione, 6), [Cu(phendione)3]-
(ClO4)2·4H2O (12) and [Ag(phendione)2]ClO4 (13) are highly active, in vitro, against a range of normal
and cancerous mammalian cells, fungal and insect cell lines, with the metal complexes offering a clear
enhancement in activity. Cytoselectivity was not observed between the tumorigenic and non-tumorigenic
mammalian lines. In in vivo tests, using Galleria mellonella and Swiss mice, all four compounds were
well tolerated in comparison to the clinical agent, cisplatin. In addition, blood samples taken from the
Swiss mice showed that the levels of the hepatic enzymes, aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), remained unaffected. Immunocompromised nude mice showed a much lower
tolerance to 13 and, subsequently, when these mice were implanted with Hep-G2 (hepatic) and HCT-8
(colon) human-derived tumors, there was no influence on tumor growth.
Introduction
Metal complexes of nitrogen-substituted, phenanthrene-based
ligands have shown significant potential as broad-spectrum
agents capable of eliciting cytotoxicity toward diseases and
infections manifested by cancer,1–8 viruses,9–11 bacteria6,12–15
and fungi.16–18 The planar, aromatic phenanthrene molecule (1)
(Fig. 1) is widely found in nature and forms the backbone of
many natural and semi-synthetic opiates, including morphine,
codeine and naloxone. A selection of heteroaromatic derivatives
of phenanthrene (2–7 and 9–11) is shown in Fig. 1, and although
the quinone derivatised compounds (4, 6 and 8) experience loss
of aromaticity at the central arene ring, they do retain their planar
structure. The N-substituted organic molecule, 9-phenanthridine (2),
has been compared structurally to the well-known polycyclic
DNA intercalator, acridine (8),19–21 and studies of the nucleotide
binding capability of cationic phenanthridinium derivatives have
already been reported.22
Early studies on the antibacterial properties of the metal-free
compounds, 1–7, revealed that inclusion of N-atoms in the
Fig. 1 Structures of selected compounds containing the phenanthrene-
type backbone.
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phenanthrene ring generally increased antimicrobial activity.15
Interestingly, the quinone (dione) derivatives, 4, 6 and 7, were
found to increase antimicrobial efficacy further and were highly
effective against the more resilient Gram-negative bacteria. In
that study, of all compounds tested (1–7), 1,10-phenanthroline-
5,6-quinone (phendione) (6) was found to be the most effective.
Indeed, when metal-free N,N′-chelating bases are found to be
bioactive, it is assumed that the sequestering of trace metals is
involved and that the resulting metal complexes are the actual
active species.13 Thus, one possible explanation for the enhanced
activity exhibited by 4 and 7 could relate to their ability to form
metal complexes via cellular O,O′ (4) or N,O (7) metal chelation.
The relationship between biological efficacy and N,N′-chelation
within this class of molecule was further strengthened through
our previous observations on the control of Candida albicans
fungal isolates by the metal-free compounds, 3, 5 and 9.16 At a
concentration of 20 μg mL−1, 1,10-phenanthroline (phen) (5)
showed potent antifungal bioactivity (0% cell growth during
24 h) while the non-chelating isomers, 3 and 9, were largely
inactive (93% and 99% cell growth, respectively). In the same
study, Ag(I), Cu(II) and Mn(II) ternary complexes, comprising 5
and malonate ligands, were also found to be highly toxic toward
C. albicans. The success of metal-free phen along with these
Ag(I), Cu(II) and Mn(II) ternary complexes is attributed to their
ability to induce extensive changes to the internal structure of
yeast cells, which included, retraction of the cytoplasm, nuclear
fragmentation and disruption of mitochondrial function leading
to apoptosis.17,24 Phen (5) is also fungicidal against the multi-
resistant filamentous fungus belonging to the Pseudallescheria
boydii/Scedosporium apiospermum complex, with the antifungal
activity being directly dependent on both cell density and phen
concentration.25
The application of metal complexes of phen (5) and its substi-
tuted quinone and quinoxaline derivatives (6, 10 and 11) as
novel antitumor agents has stimulated intensive interest, particu-
larly within the past two decades.1,8,26–35 The application of
such agents for the control of cancer, however, must be con-
sidered in conjunction with their ability to perturb the natural
intestinal microbial flora that is necessary for, among other
things, resistance to invasive pathogenic bacteria. Recently, Pt(II)
complexes of general formula [PtLCl2] (L = 6 or 10) were
reported as broad-spectrum antitumor agents which, interest-
ingly, exhibited negligible antibacterial activity (Bacillus subtilis,
Escherichia coli; MIC > 200 μg mL−1).6 However, it must be
highlighted that cisplatin alone exhibits moderate antibacterial
activity and this has been shown to potentiate the virulence of
Candida cells and enhance the risk of systemic candidiasis,
which can ultimately lead to fatalities amongst cancer patients.36
Thus, while antitumor complexes exhibiting strong cytotoxicity
toward a range of pathogens may be viewed as less obvious
cancer drug candidates, it may be worth considering the ability
of these compounds to control such virulent pathogens in con-
junction with their propensity to treat cancer, particularly where
immunosuppressive complications have arisen.
Metal complexes containing phen-type ligands represent a
class of compound that are entirely different to the current Pt(II)
clinical anticancer drugs for a number of reasons. (i) The planar,
heteroaromatic phen ligand (5) and particularly its quinoxaline
derivatives, 10 and 11, facilitate DNA binding via three
distinctive modes: (a) hydrophobic interactions in the minor
groove, (b) partial intercalation of the phen ligand into the helix
in the major groove and (c) π-stacking by metallo-intercalators
(e.g. phenazine) between base-paired regions.26,27 (ii) It has been
demonstrated that metal coordination complexes comprising
phen-type ligands enhance the in vitro activity of the oncogene,
p53, a vital tumor-suppressor gene which functions by inducing
apoptosis and preventing gene amplification and which is found
mutated in many forms of human cancer.37 Additionally, owing
to the low lying π* N aromatic orbitals present on phen (or
derivatives thereof ), bis– and tris–phen coordination complexes
are characterised spectroscopically by intense metal-to-ligand
charge-transfer transitions (MLCT),38 consequently leading to
their potential application as photochemical redox or photo-
dynamic therapeutic (PDT) agents.39–43
In our studies to date, we have prepared and screened a wide
spectrum of metal-based agents for their antimicrobial and antic-
ancer activities.16,17,23,24,32,44–48 In the majority of cases, it was
observed that Cu2+ and Ag+ complexes containing phendione (6)
ligands exhibit excellent biological activity and represent a class
of DNA-targeting compounds capable of inhibiting nucleotide
synthesis.5,16 As a logical progression of these studies, and given
that very few reports exist in the literature on the in vivo potential
of metal-phen adducts, the present paper details both the in vitro
and in vivo chemotherapeutic potential, drug toxicity profiles
and mechanistic aspects of phen (5), phendione (6) and Cu2+
and Ag+ complexes of 6, namely [Cu(phendione)3]-
(ClO4)2·4H2O (12)
23 and [Ag(phendione)2]ClO4 (13)
23 (Fig. 2).
Specifically, we report the in vitro cytotoxicity against mamma-
lian tumor and non-tumor lines, macrophages, insect and fungal
cell lines, the in vivo tolerance of larvae of the insect Galleria
mellonella, the in vivo tolerance of 13 within Swiss and nude
mice, and nude mouse xenograft studies of 13 against the
human-derived, implanted tumors HCT-8 (colon) and Hep-G2
(kidney).
Experimental
Synthesis
Chemicals were purchased from Sigma-Aldrich Ireland and used
as received. 1,10-Phenanthroline-5,6-quinone (phendione (6)),50
[Cu(phendione)3](ClO4)2·4H2O and [Ag(phendione)2]ClO4
were prepared in accordance with the literature methods.23
Fig. 2 Structures of [Cu(phendione)3](ClO4)2 (12)
23,49 and [Ag(phen-
dione)2]ClO4 (13).
23
48 | Toxicol. Res., 2012, 1, 47–54 This journal is © The Royal Society of Chemistry 2012
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G. Mellonella toxicity
G. mellonella larvae in the 6th developmental stage were used to
determine the in vivo cytotoxicity of 5, 6, 12, 13 and cisplatin.
Thirty healthy larvae between 0.200–0.400 g in weight and with
no cuticle discolouration were used for each experiment. Fresh
solutions of the test compounds were prepared immediately prior
to testing under sterile conditions. Each compound (0.05 g) was
dissolved in DMSO (1 cm3) and added to sterile water (9 cm3)
to give a stock solution of concentration 5000 mg cm−3. Each
compound was tested across the concentration range
5000–200 μg cm−3. Test solutions (20 μL) were administered to
the larvae by injection directly into the haemocoel through the
last pro-leg. The base of the pro-leg can be opened by applying
gentle pressure to the sides of the larvae and this aperture will
re-seal after removal of the syringe without leaving a scar.
Larvae were placed in sterile Petri dishes and incubated at 30 °C
for 72 h. The survival of the larvae was monitored every 24 h.
Death was assessed by the lack of movement in response to
stimulus together with discolouration of the cuticle. Three con-
trols were employed in all assays. The first consisted of
untouched larvae maintained at the same temperature as the test
larvae. The second was larvae with the pro-leg pierced with an
inoculation needle but no solution injected. The third control
was larvae that were inoculated with 20 μL of sterile distilled
water.
Antimicrobial assessment
Pseudallescheria boydii (RKI07_0416) belongs to the clade 4 of
the Pseudallescheria boydii/Scedosporium apiospermum
complex as previously proposed by Gilgado and co-workers.51
The fungus was grown on Sabouraud-dextrose agar (containing
2% glucose, 1% peptone, 0.5% yeast extract and 2% agar) plates
at 25 °C for 7 days. Conidia were harvested and washed with
sterile 10 mM phosphate-buffered saline (PBS, pH 7.2). The
cells were separated by gauze filtration, then collected by
centrifugation and washed three times in PBS.25 Cell density
was estimated by counting the conidia in a Neubauer chamber.
Cytotoxicity assays
In order to determine the cytotoxicity of the phen (5) and its
derivatives, different concentrations of each compound (ranging
from 10 to 0.0001 μg mL−1) were placed in contact with the cell
cultures and incubated at 37 °C in a 5% CO2 atmosphere for
24 h, except for insect cell line in which the incubation was at
27 °C. After that, cellular viability was evaluated by the neutral
red dye-uptake method.52 Briefly, cells were incubated in the
presence of 0.01% neutral red solution for 3 h at 37 °C in a 5%
CO2 atmosphere. The medium was then removed and the cells
were fixed with 4% formalin in PBS (pH 7.2). The dye incorpo-
rated by the viable cells was eluted using a mixture of methanol :
acetic acid : water (50 : 1 : 49), and the dye uptake was deter-
mined by measuring the optical density (OD) of the eluate at
490 nm in an automatic spectrophotometer (ELx800TM-
Bio-TeK Instruments, Inc.). The 50% cytotoxic concentration
(CC50) was defined as the compound concentration which
caused a 50% reduction in the number of viable cells.
Acute toxicity testing in Swiss mice
All animal experiments were performed according to the Brazi-
lian Animal Protection Laws and with approval from the local
responsible authorities at the Instituto de Microbiologia Paulo de
Góes (IMPG), Universidade Federal do Rio de Janeiro. The
acute toxicity tests were performed with albino Swiss mice
(females) weighing 20 ± 2 g, which were obtained from Institute
of Microbiology Prof. Paulo de Góes-UFRJ facilities. For each
inhibitor concentration tested five mice were used, having been
applied volumes of 0.1 ml containing compounds in concen-
trations ranging from 15 to 450 mg kg−1 administered by intra-
peritoneal route. The control group received no injection and one
group of animals received injections containing DMSO 10%
(concentration of DMSO used to dilute the drugs). After the
injections, the animals were observed during the first 5 h and
thereafter every 6 to 12 h until a total of 168 h (7 days).
Chronic toxicity testing in Swiss mice
Chronic toxicity tests were performed using an inhibitor concent-
ration equivalent to 45 mg kg−1. The intraperitoneal injections
were conducted daily for 5 consecutive days. All compounds
were diluted in DMSO (10%) and the volume injected was
0.1 ml. A control was carried out with a mice group that did not
receive an injection and another group that were injected for
5 consecutive days only with DMSO 10%. After receiving all of
the injections the animals were monitored for 7 days and blood
samples were collected and processed at the clinical laboratory
of the Faculty of Pharmacy, UFRJ. Sera sample were used to
determine the levels of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) enzymes, which are used as
markers of liver integrity (Labtest, Lagoa Santa, MG, Brazil).
In vivo xenograft experiments using nude mice
All animal experiments were performed according to the
German Animal Protection Law and with approval from the
local responsible authorities. Crl : NMRI.nu/nu mice were
purchased from Charles River (Sulzfeld, Germany) and main-
tained under standardized (22 ± 2 °C, 50 ± 10% relative humid-
ity, 12 h light–dark-rhythm) and pathogen-free conditions. For
the approximate tolerability test, tumor-free male mice were
administered once i.p. with complex 13. Behavioural anomalies,
body weight, body weight change (BWC, in relation to the first
measurement in %) and mortality were registered. In the thera-
peutic experiments, the mice received, at day zero, 107 Hep-G2
(human hepatocellular carcinoma or HCT-8 (human colon carci-
noma) cells subcutaneously into the left flank. When tumors
were palpable (day 22 for Hep G2, day 8 for HCT-8) the mice
were randomized to the corresponding treatment groups. Treat-
ment was performed in a q4dx3 schedule i.p. Tumor sizes were
measured twice per week with a caliper and tumor volumes were
calculated according to length × width2/0.5. Treated to control
(T/C) values of mean tumor volumes were calculated at each
measurement day and the optimum (lowest) value was recorded.
Additionally, body weight was determined twice per week as an
estimation of tolerability. Blood samples from 5 mice per group
were taken from the retroorbital bulbus 4 days after initiation of
This journal is © The Royal Society of Chemistry 2012 Toxicol. Res., 2012, 1, 47–54 | 49
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treatment and blood parameters (WBC white blood cells, throm.
thrombocytes) were determined with a Coulter counter. The
experiments were finished for ethical reasons at day 45 or 22,
respectively.
Results and discussion
In almost every case, metal-free phendione (6) was considerably
more cytotoxic than metal-free phen (5) (Table 1). When viewed
in terms of micromolar concentrations, a further notable
enhancement in activity was observed on progressing from 6 to
the Cu2+ complex, 12. Furthermore, with the exception of
C. albicans, the Ag+ complex, 13, was less potent than 12. For
most of the cell lines, 13 was more active than metal-free 6. The
general order of activity for the four test compounds is as
follows: 12 > 13 > 6 > 5. The test compounds showed higher
activities toward the human derived tumor and normal cell lines
and fungal cell lines when compared to murine (except S49 and
S180), simian and insect-derived cell lines. From the IC50 values
shown in Table 1 it is evident that peritoneal mouse macrophages
(MΦ) and the insect cell line from Aedes albopictus (C6/36)
(both >10(55)) are, in general, more tolerant to all of the test
compounds.
The increasing prevalence of fungal infections, especially
hospital-acquired infections and infections in immunocompro-
mised patients, has highlighted the need for novel antifungal
treatments. Corroborating this finding, drug-resistant fungal
isolates have been reported for all known classes of antifungal
agents.53 In this context, invasive Pseudallescheria/Scedosporium
infections in immunocompromised individuals are characterized
by high morbidity and mortality as well as poor response to
amphotericin B.54 In their search for possible virulence attributes
expressed by this collection of fungi,55 Silva and co-workers56,57
and Pereira and co-workers58 described the production of both
secreted and cell-associated metallo-type proteases involved in
the cleavage of relevant human protein structures, like serum
proteins and extracellular matrix components. As expected,
metalloprotease inhibitors (e.g., phen (5) and EDTA) were able
to block several essential biological processes in P. boydii,
including cell viability, conidia into mycelia differentiation and
secretion of proteins.25 These findings suggest that metallo-type
enzymes could be potential targets for future therapeutic inter-
vention against P. boydii. The results reported here support this
premise, since phen (5) (at the micromolar level) and particularly
phendione (6) and its Ag+ and Cu2+ complexes, 12 and 13
(at the nanomolar level) were able to powerfully reduce the coni-
dial viability of P. boydii as compared to the susceptibility of
different animal/insect lineages (Table 1). Our observations on
the biological effects of metal-free phen (5) and phendione (6)
may be attributable to cellular metal chelation.
Larvae of the insect Galleria mellonella (the greater wax
moth) were employed to assess the in vivo cytotoxic tolerance of
the test compounds (Table 2).32,59,60 Insect larvae have been
widely used as a convenient and inexpensive in vivo screening
model to assess the therapeutic potential of novel antimicrobial
drugs18 and have yielded results that are considered comparable
to those obtained using mammalian models.61,62 The innate
defences of insects, including G. mellonella, like those of
mammals, consist of structural and passive barriers as well as
humoral and cellular responses within the haemolymph (analo-
gous to the blood of mammals).60 Indeed, cellular responses
within the haemolymph are often activated by signal
Table 1 Inhibitory concentration 50% (IC50) values
a (μg mL−1 and
(μM)) for compounds 5, 6, 12 and 13 against a variety of cell lineagesb
Cell lineages
Cytotoxicity IC50 μg mL
−1 (μM)
Tested compounds
5 6 12 13
Vero >10 (55) 6.6 (31.4) 6.5 (6.7) >10 (15.9)
MA-104 >10 (55) 3.9 (18.6) 4.4 (4.6) 7.3 (11.6)
LLC-MK2 >10 (55) 7.4 (35.2)) 6.8 (7.0) 9.1 (14.5)
CHO >10 (55) 7.9 (37.6) 9.2 (9.5) >10 (15.9)
S497 n.t. 0.0118 (0.056) n.t. n.t.
S1807 n.t. 0.0088 (0.042) n.t. n.t.
RAW >10 (55) 5.6 (26.6) 6.1 (6.3) >10 (15.9)
MΦ >10 (55) >10 (48) >10 (10) >10 (15.9)
MRC-5 >10 (55) 7.6 (36.2) 7.6 (7.9) 7.4 (11.8)
HEp-2 >10 (55) 8.8 (41.9) >10 (10) >10 (15.9)
A549 >10 (55) 8.5 (40.4) 8.2 (8.5) >10 (15.9)
DLKP23 0.35 (1.9) 0.008 (0.04) n.t. 0.025 (0.04)
A49824 1.05 (5.8) 0.88 (4.2) 0.85 (0.88) 0.88 (1.4)
HK-224 0.94 (5.2) 0.15 (0.7) 0.48 (0.5) 0.50 (0.8)
Hep-G224 0.74 (4.1) 0.29 (1.4) 0.75 (0.78) 0.54 (0.86)
Chang24 1.32 (7.3) 0.08 (0.4) 0.19 (0.2) 0.19 (0.3)
C6/36 >10 (55) >10 (48) >10 (10) >10 (15.9)
P. boydii conidia 0.473 (2.62) 0.032 (0.15) 0.096 (0.1) 0.116 (0.18)
C. albicans
yeasts23
2.5 (13.9) 0.6 (2.9) 1.3 (1.3) 0.3 (0.48)
a IC50 μg mL
−1 (μM) values for all cells except C. albicans where the
MIC100 μg mL
−1 (μM) values are quoted.23 Cell lineages: Vero (African
green monkey kidney cell), MA-104 (kidney embryonic cell of Rhesus
monkey), LLC-MK2 (kidney cell of Rhesus monkey), CHO (Chinese
hamster ovary cells), S49 (mouse lymphoma cells), S180 (mouse cancer
cells), RAW 264.7 (murine macrophages), MΦ (peritoneal mouse
macrophages), HEp-2 (human larynx carcinoma cells), A549 (human
Caucasian lung carcinoma), DLKP cells (human lung carcinoma cell
line), A-498 (human renal carcinoma cell line), HK-2 (human renal
normal cell line), Hep-G2 (human liver carcinoma cell line), Chang
(human liver normal cell line), MRC-5 (human lung fibroblast), C6/36
(insect cell line from Aedes albopictus). b n.t. = not tested.
Table 2 Mortality (%) of G. mellonella larvae 72 h post injection with
various dosages of test compounds
Compound μg per larvae
Administered amount/% mortality
100 40 20 10 2
5 % Mortality 100% 80% 80% 0% 0%
μmol 0.554 0.222 0.111 0.055 0.011
mg kg−1 333.3 133.3 67.67 33.33 6.67
6 % Mortality 90% 80% 80% 0% 0%
μmol 0.475 0.190 0.095 0.047 0.001
mg kg−1 333.3 133.3 67.67 33.33 6.67
12 % Mortality 90% 80% 80% 0% 0%
μmol 0.103 0.041 0.020 0.010 0.002
mg kg−1 333.3 133.3 67.67 33.33 6.67
13 % Mortality 90% 80% 80% 0% 0%
μmol 0.159 0.063 0.031 0.016 0.003
mg kg−1 333.3 133.3 67.67 33.33 6.67
Cisplatin % Mortality 100% 100% 100% 60% 0%
μmol 0.333 0.133 0.066 0.033 0.007
mg kg−1 333.3 133.3 67.67 33.33 6.67
50 | Toxicol. Res., 2012, 1, 47–54 This journal is © The Royal Society of Chemistry 2012
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transduction systems comparable to those in mice, and results
obtained using insects strongly correlate with results got from
murine testing.63,64 Data for the survival of G. mellonella larvae
(expressed as a %) as a function of administered dosages of the
test compounds and cisplatin are displayed in Table 2. At the
highest administered concentration (100 μg per larvae) 10% of
larvae treated with 6 and its Cu(II) and Ag(I) complexes, 12 and
13, respectively, survived, whilst all of the larvae died when
injected with 5 and cisplatin. At concentrations of 40 μg per
larvae and 20 μg per larvae, 20% of the insects exposed to 5, 6,
12 and 13 survived, whilst all of those subjected to cisplatin per-
ished. At a dosage of 10 μg per larvae all larvae treated with 5,
6, 12 and 13 were alive after 72 h, compared to just 40% survi-
val for those treated with cisplatin. All of the cisplatin-treated
larvae survived at a dosage of 2 μg per larvae. Thus, it is clear
that cisplatin is considerably more toxic to G. mellonella than 5,
6, 12 and 13. When viewed in terms of complete tolerance
(expressed as μmol per larvae) of G. mellonella the relative order
is: 5 ≈ 6≫ 13 > 12 > cisplatin.
In a related sequence of experiments, Swiss mice were
injected with all of the test compounds across the concentration
range 15–450 mg kg−1 and mortality (%) monitored every 24,
72 and 168 h (Table 3). Up to a dosage of 45 mg kg−1 no deaths
were recorded 168 h post administration of the compounds.
When the dose was increased to 150 mg kg−1 all of the mice
exposed to 5 and the silver(I) complex, 13, survived. However, at
this concentration 20% and 60% of mice treated with 6 and the
copper(II) complex, 12, respectively, were dead after 72 h, and
the number of deaths increased after a further 96 h (to 80% in
each case). A further doubling of the dosage, to 300 mg kg−1,
did not induce death in any of the mice exposed to 5. However,
at this concentration all of the mice treated with 12 had perished
at 24 h and a significant number of those treated with 6 and 13
also died (80% and 40%, respectively) at the same time period.
No further fatalities were observed with 6 and 13 after a further
144 h. At the highest dosage used for each compound (450 mg
kg−1) there were no survivors at 24 h post administration. At this
high concentration, almost immediately after the administration
of the compounds, the animals presented strong convulsions,
some of them died few hours after injection. In conclusion, the
tolerance of Swiss mice is in the order 5 > 13 > 6 > 12. This
trend is similar to that observed in the G. mellonella tests, with
the exception that the relative tolerance of 6 and 13 was reversed.
For G. mellonella and Swiss mice, 5 was the least toxic and the
copper(II) complex, 12, was the most.
Chronic toxicity tests were then conducted in which Swiss
mice were inoculated daily with 45 mg kg−1 of each test com-
pound during 5 consecutive days. After this time period, the
animals were monitored for an additional 7 days. The results
showed that in all cases the mice survived this treatment proto-
col. Moreover, through visual analyses, the animals remained
well throughout the treatment and no behavioural changes were
detected. The animals were fed normally and, consequently,
there were no differences in body weight of animals treated with
PBS (control system), phen (5), phendione (6) or phen-deriva-
tives 12 and 13 (data not shown). At the end of the experiment,
the animals were sacrificed and the blood was collected in order
to measure two distinct hepatic enzymes, as possible markers for
the toxicity of these compounds (Fig. 3). No differences were
detected in the level of both hepatic enzymatic activities of
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) in non-treated animals and also in those treated with the
test compounds.
Given that the toxicity towards both G. mellonella and Swiss
mice of the Ag+ complex, 13, was less than that of the Cu2+
complex, 12, and indeed also that of cisplatin, and also in con-
junction with the encouraging AST and ALT enzymatic profile
expression, complex 13 was selected for further in vivo investi-
gations. The cytotoxicity of 13 for male nude mice (without
tumors) was established by treating the mice with a series of
different concentrations of the Ag+ complex (2.5–400 mg kg−1
per inj.) (Table 4). Complex 13 was dissolved in DMSO (end
concentration 10%) and further diluted with 0.5% Tween 80 in
saline. Mice were injected intraperitoneally (i.p.) with a known
concentration of 13 at day 0 only and the effects noted. The
complex induced a clear, dose-dependent mortality and body
weight loss (BWC). Immediately after injection, the mice
showed strong convulsions lasting for about 2 min. At necropsy,
inflammation of the gut and pathological livers were obvious
(data not shown). The maximum tolerated dose (MTD) of 13 was
estimated to be 10 mg kg−1 (0.016 mmol kg−1). It is interesting
to note that Swiss mice appear to withstand up to 150 mg kg−1
of 13 in the acute toxicity tests (and 45 mg kg−1 in chronic toxi-
city tests), whereas the nude mice (without implanted tumors)
can only tolerate 10 mg kg−1 of the Ag+ complex.
A similar xenograft study was conducted using solutions of
13 on nude mice transplanted with human HCT-8 colon carci-
noma cells. In total, 24 mice were transplanted with the HCT-8
cells and all were included in the treatment and evaluation. Treat-
ment started at palpable tumors (day 8). In two groups, 13 was
Table 3 Mortality (%) of Swiss mice after treatment with 5, 6, 12 and
13
Compound
Dose
(mg kg−1 d−1)
Dose
(mmol kg−1 d−1)
% Mortality
Exposure (h)
24 h 72 h 168 h
5 15 0.083 0% 0% 0%
30 0.166 0% 0% 0%
45 0.249 0% 0% 0%
150 0.830 0% 0% 0%
300 1.660 0% 0% 0%
450 2.790 100% — —
6 15 0.071 0% 0% 0%
30 0.142 0% 0% 0%
45 0.213 0% 0% 0%
150 0.710 0% 20% 80%
300 1.420 80% 80% 80%
450 2.130 100% — —
12 15 0.016 0% 0% 0%
30 0.032 0% 0% 0%
45 0.048 0% 0% 0%
150 0.160 0% 60% 80%
300 0.320 100% — —
450 0.480 100% — —
13 15 0.024 0% 0% 0%
30 0.048 0% 0% 0%
45 0.072 0% 0% 0%
150 0.240 0% 0% 0%
300 0.480 40% 40% 40%
450 0.720 100% — —
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again administered at doses of 5 and 10 mg kg−1 per injection
on days 8, 12 and 16 (Table 5 and Fig. 4). The experiment was
terminated at day 22 because of the appearance of large tumors
in some mice. Again, 13 had no influence on tumor growth
at either of the administered doses. As was the case with the
Hep-G2 xenografts, 13 induced a dose-dependent body weight
loss, but had no influence on blood parameter.
The results obtained here for complex 13 contrast with
those previously reported for the treatment of implanted
human-derived solid tumors by the V(IV) dimethylated-phen
complex, METVAN (bis(4,7-dimethyl-1,10-phenanthroline)-
sulfato-oxovanadium(IV) {[VO(SO4)(Me2-Phen)2]}),
1 and the
La(III) complex, KP772 {tris(1,10-phenanthroline)-lanthanum
(III)-trithiocyanate}.8 METVAN, administered (i.p.) for 5 days
per week for 4 weeks at 10 mg kg−1 d−1, resulted in significant
delayed tumor progression in SCID mouse xenograft models
against both human glioblastoma and breast cancer. Additionally,
KP772, administered (intravenously) on days 0–4 at 4, 8 or
12 mg kg−1 d−1 also displayed significant, dose-dependent,
delayed tumor progression toward DLD-1 human colon implanted
mice by day 14. These results compared favorably to the parallel
xenograft experiment conducted on the reduction in tumor volume
by cisplatin, which was administered at 2 mg kg−1 d−1 between
days 0–4.8 However, it should be highlighted that in Rosenberg
et al.’s original report on the in vivo efficacy of cisplatin against
implanted sarcoma-180, administered by single injection at
8 mg kg−1 on day 8, complete eradication of that particular tumor
was observed by day 36.65 It should be noted however, direct
comparisons between the intravenously applied agent KP772 and
13, which was applied intraperitoneally, are not possible here,
particularly as the interaction with serum iron could be significant
in the anticancer activity of phenanthroline compounds.
Fig. 3 Levels of hepatic enzymatic activities (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) in non-treated Swiss mice and
in mice treated with 5, 6, 12 and 13.
Table 4 Results of approximative toxicity tests for complex 13 against male nude mice (without implanted tumor cells)
Group
Nude mice Tested Treatment Dose Toxic BWCb
Tested Compound (d)a (mg kg−1 per inj.) Deaths (d)a (%)
1A 2 13 0 2.5 0 0
1B 2 13 0 5 0 −2
1C 2 13 0 10 0 −11
1D 2 13 0 20 2 (5) −20
2A 2 13 0 25 2 (3) −9
2B 2 13 0 50 2 (3) −7
2C 2 13 0 100 2 (1) n.t.
2D 2 13 0 200 2 (1) n.t.
2E 2 13 0 400 2 (1) n.t.
a d = day. bBWC = body weight change.
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Conclusions
Derivatization of the ligand phen (5) to phen-dione (6) results in
a substantial cytotoxic enhancement against nearly all cell
lineages tested. Moreover, upon complexation of 6 to yield
[Cu(phendione)3](ClO4)2·4H2O (12) and [Ag(phendione)2]ClO4
(13) a further enhancement is evident, particularly against the
human-derived tumor lines (MRC-5, HEp-2, A549, DLKP,
A498 and Hep-G2) with most IC50 (μM) values decreasing by at
least 50% compared with the metal-free phendione (6) ligand.
Cytoselectivity was not observed as both metal complexes were
more toxic toward the non-cancerous liver (Chang) and renal
(HK-2) cells compared to the respective tumor lines, Hep-G2
and A498. While the Cu2+ complex, 12, was more active against
the multi-resistant fungi P. boydii, than its Ag+ counterpart, 13, it
was the latter complex which exhibited better activity against
C. albicans. Overall, both 12 and 13 can be described as
potent cytotoxic agents capable of eliciting low-micromolar or
nanomolar cytotoxicities against both fungal and human-derived
cell lines.
Against the insect larvae, G. mellonella, the metal-free ligands
5 and 6 displayed the greatest tolerance in vivo and complexes
12 and 13 were significantly less toxic than cisplatin. Encoura-
gingly, at a concentration of 33.3 μg kg−1 the mortality induced
by 12 and 13 was 0%, compared to 60% for cisplatin at the same
concentration. For Swiss mice, the tolerance trend was 5 > 13 >
6 > 12, and at an administered dose of 150 mg kg−1 d−1, the
Ag+ complex, 12, did not cause fatalities, whilst with the metal-
free phendione ligand (6) there was 80% mortality over the same
7 day period. In chronic in vivo toxicity studies, using Swiss
mice exposed to 45 mg kg−1 d−1 of 5, 6, 12 and 13 over 1 week,
the animals remained well throughout and there were no obvious
behavioural changes and no detectable differences in the
expression levels of AST and ALT hepatic enzymes. It is evident
that the compounds are well tolerated by both G. mellonella and
Swiss mice. In contrast to the relatively high tolerance of Swiss
mice to [Ag(phendione)2]ClO4 (13) the MTD of immuno-
compromised nude mice was significantly lower (10 mg kg−1 d−1).
Higher concentrations of 13 results in mortality coupled with
unacceptable % body weight changes in the animals. Administer-
ing 13 (at a concentration of either 5 or 10 mg kg−1 d−1) to nude
mice implanted with Hep-G2 (hepatic) or HCT-8 (colon) human-
derived tumors had no influence on tumor growth. Thus, in their
current form, these Cu(II) and Ag(I) phendione compounds
appear to offer excellent potential for the cytotoxic treatment of
both fungi and insects, however, structural modifications will be
required for the translation of this exceptional in vitro cytotox-
icity into an acceptable in vivo antitumor effect.
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